Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas

Trial Profile

Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs Carmustine (Primary) ; Temozolomide (Primary) ; Benzylguanine; Filgrastim; Plerixafor
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2017.
    • 10 Aug 2016 Status changed from suspended to active, no longer recruiting.
    • 01 Jun 2016 Time frame for primary endpoint changed from 2 years to 96 weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top